161 related articles for article (PubMed ID: 38842271)
1. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
[TBL] [Abstract][Full Text] [Related]
2. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
Li P; Cui Y; Xu X; Dong J; Liao L
Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
Lachaux M; Barrera-Chimal J; Nicol L; Rémy-Jouet I; Renet S; Dumesnil A; Wecker D; Richard V; Kolkhof P; Jaisser F; Ouvrard-Pascaud A; Mulder P
Diabetes Obes Metab; 2018 Oct; 20(10):2399-2407. PubMed ID: 29862614
[TBL] [Abstract][Full Text] [Related]
6. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
7. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
[TBL] [Abstract][Full Text] [Related]
8. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
9. Cardiorenal benefits of finerenone: protecting kidney and heart.
González-Juanatey JR; Górriz JL; Ortiz A; Valle A; Soler MJ; Facila L
Ann Med; 2023 Dec; 55(1):502-513. PubMed ID: 36719097
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
Bonnard B; Pieronne-Deperrois M; Djerada Z; Elmoghrabi S; Kolkhof P; Ouvrard-Pascaud A; Mulder P; Jaisser F; Messaoudi S
J Mol Cell Cardiol; 2018 Aug; 121():124-133. PubMed ID: 29981797
[TBL] [Abstract][Full Text] [Related]
11. Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
Ruilope LM; Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Sarafidis P; Schmieder RE; Joseph A; Rethemeier N; Nowack C; Bakris GL;
Hypertension; 2022 Dec; 79(12):2685-2695. PubMed ID: 36252131
[TBL] [Abstract][Full Text] [Related]
12. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
[TBL] [Abstract][Full Text] [Related]
13. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Agarwal R; Anker SD; Bakris G; Filippatos G; Pitt B; Rossing P; Ruilope L; Gebel M; Kolkhof P; Nowack C; Joseph A;
Nephrol Dial Transplant; 2022 May; 37(6):1014-1023. PubMed ID: 33280027
[TBL] [Abstract][Full Text] [Related]
14. Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Haller H
Herz; 2022 Oct; 47(5):401-409. PubMed ID: 36094559
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
Lattenist L; Lechner SM; Messaoudi S; Le Mercier A; El Moghrabi S; Prince S; Bobadilla NA; Kolkhof P; Jaisser F; Barrera-Chimal J
Hypertension; 2017 May; 69(5):870-878. PubMed ID: 28320854
[TBL] [Abstract][Full Text] [Related]
17. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
Salukhov VV; Shamkhalova MS; Duganova AV
Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
[TBL] [Abstract][Full Text] [Related]
18. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.
Lavall D; Jacobs N; Mahfoud F; Kolkhof P; Böhm M; Laufs U
Biochem Pharmacol; 2019 Oct; 168():173-183. PubMed ID: 31283930
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
[TBL] [Abstract][Full Text] [Related]
20. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
